安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Harrow
Harrow, a growing leader in the North American ophthalmic pharmaceutical market, is dedicated to delivering innovative, accessible, and affordable eyecare solutions
- Harrow Announces First-Quarter 2025 Financial Results
NASHVILLE, Tenn --(BUSINESS WIRE)--May 8, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025 The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow com
- Products - Harrow
Harrow owns an FDA-Registered 503B Outsourcing Facility and a patient-specific 503A pharmacy
- Harrow to Report First Quarter 2025 Financial Results After Market . . .
NASHVILLE, Tenn --(BUSINESS WIRE)--May 5, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close
- Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial . . .
NASHVILLE, Tenn --(BUSINESS WIRE)--Mar 27, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close
- Harrow Announces New Appointments to its Board of Directors
NASHVILLE, Tenn --(BUSINESS WIRE)--Jan 29, 2024-- Harrow (Nasdaq: HROW), a leading U S eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph D , and Lauren Silvernail to the Company’s Board of Directors, effective immediately
- Investor Relations | Harrow, Inc.
Harrow, Inc (NASDAQ: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable
- Contact - Harrow
Harrow, Inc Headquarters 1A Burton Hills Blvd , Suite 200 Nashville, TN 37215 (615) 733 4730 (615) 733 4737 (Investor Relations)
|
|
|